Eric Schmidt
Stock Analyst at Cantor Fitzgerald
(0.52)
# 3,801
Out of 4,814 analysts
47
Total ratings
20.59%
Success rate
-30.99%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eric Schmidt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMTX Immatics | Reiterates: Overweight | n/a | $4.26 | - | 4 | Apr 1, 2025 | |
| SMMT Summit Therapeutics | Initiates: Overweight | n/a | $24.61 | - | 1 | Mar 21, 2025 | |
| GLYC GlycoMimetics | Initiates: Overweight | n/a | $0.22 | - | 1 | Mar 21, 2025 | |
| ALMS Alumis | Reiterates: Overweight | n/a | $5.06 | - | 4 | Mar 20, 2025 | |
| BCAX Bicara Therapeutics | Reiterates: Overweight | $13 | $12.13 | +7.30% | 2 | Mar 13, 2025 | |
| ADCT ADC Therapeutics | Reiterates: Overweight | n/a | $1.23 | - | 2 | Mar 7, 2025 | |
| PRTA Prothena Corporation | Reiterates: Overweight | n/a | $9.23 | - | 1 | Feb 21, 2025 | |
| CRSP CRISPR Therapeutics AG | Reiterates: Neutral | n/a | $37.76 | - | 4 | Feb 19, 2025 | |
| CDTX Cidara Therapeutics | Assumes: Overweight | n/a | $19.44 | - | 1 | Jan 27, 2025 | |
| INCY Incyte | Reiterates: Neutral | n/a | $58.22 | - | 6 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $27.66 | - | 4 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.31 | - | 3 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $96 | $26.67 | +259.96% | 4 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $4.15 | - | 2 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $28.54 | - | 2 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $292 | $118.61 | +146.18% | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $370 | $489.10 | -24.35% | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.29 | - | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $0.29 | - | 1 | May 30, 2017 |
Immatics
Apr 1, 2025
Reiterates: Overweight
Price Target: n/a
Current: $4.26
Upside: -
Summit Therapeutics
Mar 21, 2025
Initiates: Overweight
Price Target: n/a
Current: $24.61
Upside: -
GlycoMimetics
Mar 21, 2025
Initiates: Overweight
Price Target: n/a
Current: $0.22
Upside: -
Alumis
Mar 20, 2025
Reiterates: Overweight
Price Target: n/a
Current: $5.06
Upside: -
Bicara Therapeutics
Mar 13, 2025
Reiterates: Overweight
Price Target: $13
Current: $12.13
Upside: +7.30%
ADC Therapeutics
Mar 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $1.23
Upside: -
Prothena Corporation
Feb 21, 2025
Reiterates: Overweight
Price Target: n/a
Current: $9.23
Upside: -
CRISPR Therapeutics AG
Feb 19, 2025
Reiterates: Neutral
Price Target: n/a
Current: $37.76
Upside: -
Cidara Therapeutics
Jan 27, 2025
Assumes: Overweight
Price Target: n/a
Current: $19.44
Upside: -
Incyte
Jan 10, 2025
Reiterates: Neutral
Price Target: n/a
Current: $58.22
Upside: -
Dec 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $27.66
Upside: -
Dec 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.31
Upside: -
Sep 18, 2024
Reiterates: Overweight
Price Target: $96
Current: $26.67
Upside: +259.96%
Sep 16, 2024
Reiterates: Neutral
Price Target: n/a
Current: $4.15
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $28.54
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $292
Current: $118.61
Upside: +146.18%
Oct 17, 2023
Reiterates: Overweight
Price Target: $370
Current: $489.10
Upside: -24.35%
Oct 17, 2023
Downgrades: Neutral
Price Target: n/a
Current: $1.29
Upside: -
May 30, 2017
Initiates: Outperform
Price Target: n/a
Current: $0.29
Upside: -